The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Emerging insights into ethnic-specific TP53 germline variants
Abstract
The recent expansion of human genomics repositories has facilitated the discovery of novel TP53 variants in populations of different ethnic origins. Interpreting TP53 variants is a major clinical challenge because they are functionally diverse, confer highly variable predisposition to cancer (including elusive low-penetrance alleles), and interact with genetic modifiers that alter tumor susceptibility. Here, we discuss how a cancer risk continuum may relate to germline TP53 mutations on the basis of our current review of genotype–phenotype studies and an integrative analysis combining functional and sequencing datasets. Our study reveals that each ancestry contains a distinct TP53 variant landscape defined by enriched ethnic-specific alleles. In particular, the discovery and characterization of suspected low-penetrance ethnic-specific variants with unique functional consequences, including P47S (African), G334R (Ashkenazi Jewish), and rs78378222 (Icelandic), may provide new insights in terms of managing cancer risk and the efficacy of therapy. Additionally, our analysis highlights infrequent variants linked to milder cancer phenotypes in various published reports that may be underdiagnosed and require further investigation, including D49H in East Asians and R181H in Europeans. Overall, the sequencing and projected functions of TP53 variants arising within ethnic populations and their interplay with modifiers, as well as the emergence of CRISPR screens and AI tools, are now rapidly improving our understanding of the cancer susceptibility spectrum, leading toward more accurate and personalized cancer risk assessments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is evidence that germline p53 dysfunction can induce inflammation in a way that is dependent on the NF-kB pathway.185,186”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Mutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history
Lalloo, F., Varley, J., Ellis, D., Moran, A., O'Dair, L., Pharoah, P., & Evans, D. G. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12856-5 · Cited by 202
Garritano, S., Gemignani, F., Palmero, E. I., Olivier, M., Martel-Planche, G., Le Calvez-Kelm, F., Brugiéres, L., Vargas, F. R., Brentani, R. R., Ashton-Prolla, P., et al. (2010) · Human Mutation · doi:10.1002/humu.21151 · Cited by 153
Pinto, E. M., Billerbeck, A. E. C., Villares, M. C. B. F., Domenice, S., Mendonça, B. B., & Latronico, A. C. (2004) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302004000500009 · Cited by 153
Research works printed but not linked: 69
- Leroy, 2014, TP53 mutations in human cancer: database reassessment and prospects for the next decade, Hum Mutat, 35, 672, 10.1002/humu.22552 · DOI · Paper page
- Malkin, 1990, Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Science, 250, 1233, 10.1126/science.1978757 · DOI · Paper page
- Rogoża-Janiszewska, 2021, Prevalence of recurrent mutations predisposing to breast cancer in early-onset breast cancer patients from Poland, Breast Cancer, 28, 226, 10.1007/s12282-020-01151-7 · DOI
- McCuaig, 2012, Routine TP53 testing for breast cancer under age 30: ready for prime time?, Fam Cancer, 11, 607, 10.1007/s10689-012-9557-z · DOI
- Sheng, 2020, Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer, Int J Cancer, 146, 487, 10.1002/ijc.32424 · DOI
- Bakhuizen, 2019, TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort, Fam Cancer, 18, 273, 10.1007/s10689-018-00118-0 · DOI
- de Andrade, 2021, Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study, Lancet Oncol, 22, 1787, 10.1016/S1470-2045(21)00580-5 · DOI · Paper page
- Kratz, 2017, Cancer screening recommendations for individuals with Li-Fraumeni syndrome, Clin Cancer Res, 23, e38, 10.1158/1078-0432.CCR-17-0408 · DOI · Paper page
- de Andrade, 2017, Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history, Hum Mutat, 38, 1723, 10.1002/humu.23320 · DOI
- de Andrade, 2022, The TP53 database: transition from the International Agency for Research on Cancer to the US National Cancer Institute, Cell Death Differ, 29, 1071, 10.1038/s41418-022-00976-3 · DOI · Paper page
- Karczewski, 2020, The mutational constraint spectrum quantified from variation in 141,456 humans, Nature, 581, 434, 10.1038/s41586-020-2308-7 · DOI · Paper page
- Hainaut, 2016, Somatic TP53 mutations in the era of genome sequencing, Cold Spring Harb Perspect Med, 6, a026179, 10.1101/cshperspect.a026179 · DOI · Paper page
- Kotler, 2018, A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation, Mol Cell, 71, 178, 10.1016/j.molcel.2018.06.012 · DOI · Paper page
- Hoyos, 2022, Fundamental immune-oncogenicity trade-offs define driver mutation fitness, Nature, 606, 172, 10.1038/s41586-022-04696-z · DOI
- Barnoud, 2019, Common genetic variants in the TP53 pathway and their impact on cancer, J Mol Cell Biol, 11, 578, 10.1093/jmcb/mjz052 · DOI
- Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc Natl Acad Sci USA., 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
- Xu, 2011, Gain of function of mutant p53 by coaggregation with multiple tumor suppressors, Nat Chem Biol, 7, 285, 10.1038/nchembio.546 · DOI · Paper page
- Kratz, 2021, Analysis of the Li-Fraumeni spectrum based on an international germline TP53 variant data set: an international agency for research on cancer TP53 database analysis, JAMA Oncol, 7, 1800, 10.1001/jamaoncol.2021.4398 · DOI
- Fischer, 2018, Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity, JCI Insight, 3, e121364, 10.1172/jci.insight.121364 · DOI
- Fischer, 2018, Association between the oligomeric status of p53 and clinical outcomes in Li-Fraumeni syndrome, J Natl Cancer Inst, 110, 1418, 10.1093/jnci/djy114 · DOI
- Xu, 2014, Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations, Sci Rep, 4, 4223, 10.1038/srep04223 · DOI
- Monti, 2007, Transcriptional functionality of germ line p53 mutants influences cancer phenotype, Clin Cancer Res, 13, 3789, 10.1158/1078-0432.CCR-06-2545 · DOI · Paper page
- Fischer, 2016, p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis, Cell Cycle, 15, 3210, 10.1080/15384101.2016.1241917 · DOI
- Gonzalez, 2009, Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations, J Clin Oncol, 27, 1250, 10.1200/JCO.2008.16.6959 · DOI · Paper page
- McBride, 2017, Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?, Fam Cancer, 16, 423, 10.1007/s10689-016-9964-7 · DOI
- Beckman, 1994, Is p53 polymorphism maintained by natural selection?, Hum Hered., 44, 266, 10.1159/000154228 · DOI · Paper page
- Shi, 2009, Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia, Am J Hum Genet, 84, 534, 10.1016/j.ajhg.2009.03.009 · DOI
- Kung, 2016, The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction, Cell Rep, 14, 2413, 10.1016/j.celrep.2016.02.037 · DOI · Paper page
- Dumont, 2003, The codon 72 polymorphic variants of p53 have markedly different apoptotic potential, Nat Genet, 33, 357, 10.1038/ng1093 · DOI · Paper page
- Kung, 2017, The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation, Cancer Biol Ther, 18, 484, 10.1080/15384047.2017.1323595 · DOI
- Whibley, 2009, p53 polymorphisms: cancer implications, Nat Rev Cancer, 9, 95, 10.1038/nrc2584 · DOI · Paper page
- Felley-Bosco, 1993, Functional studies of a germ-line polymorphism at codon 47 within the p53 gene, Am J Hum Genet, 53, 752
- Jennis, 2016, An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model, Genes Dev, 30, 918, 10.1101/gad.275891.115 · DOI · Paper page
- Murphy, 2017, A functionally significant SNP in TP53 and breast cancer risk in African-American women, NPJ Breast Cancer, 3, 5, 10.1038/s41523-017-0007-9 · DOI
- Li, 2005, Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response, J Biol Chem, 280, 16843, 10.1074/jbc.M410119200 · DOI
- Barnoud, 2018, Tailoring chemotherapy for the African-Centric S47 variant of TP53, Cancer Res, 78, 5694, 10.1158/0008-5472.CAN-18-1327 · DOI
- Singh, 2020, African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin, Nat Commun, 11, 473, 10.1038/s41467-019-14151-9 · DOI
- Gnanapradeepan, 2020, Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser, Elife, 9, e55994, 10.7554/eLife.55994 · DOI
- Macaulay, 2018, The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome, Fam Cancer, 17, 607, 10.1007/s10689-018-0075-5 · DOI
- Doffe, 2021, Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene, Cell Death Differ, 28, 1477, 10.1038/s41418-020-00672-0 · DOI
- Park, 2016, Germline TP53 mutation and clinical characteristics of Korean patients with Li-Fraumeni syndrome, Ann Lab Med, 36, 463, 10.3343/alm.2016.36.5.463 · DOI
- Yamaguchi, 2016, Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients, Biomed Res, 37, 259, 10.2220/biomedres.37.259 · DOI
- Yamazaki, 2018, Nodular lymphocyte-predominant hodgkin lymphoma in a 15-year-old boy with Li-Fraumeni syndrome having a germline TP53 D49H mutation, J Pediatr Hematol Oncol, 40, e195, 10.1097/MPH.0000000000000948 · DOI
- Lee, 2010, Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein, Biochemistry, 49, 9964, 10.1021/bi1012996 · DOI · Paper page
- Cho, 2013, A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer, Ann Lab Med, 33, 212, 10.3343/alm.2013.33.3.212 · DOI
- Light, 2023, Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis, Nat Commun, 14, 77, 10.1038/s41467-022-35727-y · DOI
- Miyaki, 2003, A novel case with germline p53 gene mutation having concurrent multiple primary colon tumours, Gut, 52, 304, 10.1136/gut.52.2.304 · DOI
- Pinto, 2020, What 20 years of research has taught us about the TP53 p.R337H mutation, Cancer, 126, 4678, 10.1002/cncr.33143 · DOI · Paper page
- DiGiammarino, 2002, A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer, Nat Struct Biol, 9, 12, 10.1038/nsb730 · DOI · Paper page
- Wasserman, 2015, Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study, J Clin Oncol, 33, 602, 10.1200/JCO.2013.52.6863 · DOI · Paper page
- Pinto, 2020, XAF1 as a modifier of p53 function and cancer susceptibility, Sci Adv, 6, eaba3231, 10.1126/sciadv.aba3231 · DOI
- Park, 2018, Mouse homolog of the human TP53 R337H mutation reveals its role in tumorigenesis, Cancer Res, 78, 5375, 10.1158/0008-5472.CAN-18-0016 · DOI
- Jeffers, 2021, The common germline TP53-R337H mutation is hypomorphic and confers incomplete penetrance and late tumor onset in a mouse model, Cancer Res, 81, 2442, 10.1158/0008-5472.CAN-20-1750 · DOI
- Powers, 2020, A rare TP53 mutation predominant in Ashkenazi Jews confers risk of multiple cancers, Cancer Res, 80, 3732, 10.1158/0008-5472.CAN-20-1390 · DOI
- Stacey, 2011, Germline variant in the TP53 polyadenylation signal confers cancer susceptibility, Nat Genet, 43, 1098, 10.1038/ng.926 · DOI · Paper page
- Li, 2013, Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program, Blood, 121, 4529, 10.1182/blood-2012-12-471722 · DOI
- Egan, 2012, Rare TP53 genetic variant associated with glioma risk and outcome, J Med Genet, 49, 420, 10.1136/jmedgenet-2012-100941 · DOI
- Zhou, 2012, LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53, Life Sci, 91, 358, 10.1016/j.lfs.2012.08.005 · doi:10.1016/j.lfs.2012.08.005
- Enciso-Mora, 2013, Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222, Br J Cancer, 108, 2178, 10.1038/bjc.2013.155 · doi:10.1038/bjc.2013.155
- Diskin, 2014, Rare variants in TP53 and susceptibility to neuroblastoma, J Natl Cancer Inst, 106, dju047, 10.1093/jnci/dju047 · DOI
- Macedo, 2016, Rare germline variant (rs78378222) in the TP53 3' UTR: evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome, Cancer Genet, 209, 97, 10.1016/j.cancergen.2015.12.012 · DOI
- Redman-Rivera, 2021, Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes, Nat Commun, 12, 5184, 10.1038/s41467-021-25359-z · DOI
- Erwood, 2022, Saturation variant interpretation using CRISPR prime editing, Nat Biotechnol, 40, 885, 10.1038/s41587-021-01201-1 · DOI · Paper page
- Raad, 2021, Blood functional assay for rapid clinical interpretation of germline TP53 variants, J Med Genet, 58, 796, 10.1136/jmedgenet-2020-107059 · DOI
- Zerdoumi, 2017, TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage, Hum Mol Genet, 26, 2812, 10.1093/hmg/ddx165 · DOI
- Leung, 2023, Common activities and predictive gene signature identified for genetic hypomorphs of TP53, Proc Natl Acad Sci USA., 120, e2212940120, 10.1073/pnas.2212940120 · DOI
- Noguchi, 2022, Artificial intelligence program to predict p53 mutations in ulcerative colitis-associated cancer or dysplasia, Inflamm Bowel Dis, 28, 1072, 10.1093/ibd/izab350 · DOI
- Ma, 2022, Artificial intelligence based study association between p53 gene polymorphism and endometriosis: a systematic review and meta-analysis, Comput Intell Neurosci, 2022, 8568820, 10.1155/2022/8568820 · DOI
- Ben-Cohen, 2022, TP53_PROF: a machine learning model to predict impact of missense mutations in TP53, Brief Bioinform, 23, bbab524, 10.1093/bib/bbab524 · DOI
Cited by
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Fischer, N. W., Ma, Y.-H. V., & Gariépy, J.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-06-23
- Volume
- 115
- Issue
- 10
- Pages
- 1145-1156
- ISSN
- 0027-8874
- 1460-2105
- Cited by
- 20
- References
- 6
- Language
- en
- Funders
- Canadian Institutes of Health Research (125862, 148556)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging insights into ethnic-specific TP53 germline variants. https://app.cochat.ai/papers/10.1093/jnci/djad106
- The paper
- Fischer, N. W., Ma, Y.-H. V., & Gariépy, J. (2023). Emerging insights into ethnic-specific TP53 germline variants. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.